Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle

Muscle Nerve. 2014 Jun;49(6):919-21. doi: 10.1002/mus.24160.


Introduction: Skeletal muscle ischemia-reperfusion injury (I-R) is a complex injury process that includes damage to the sarcolemmal membrane, contributing to necrosis and apoptosis. MG53, a muscle-specific TRIM family protein, has been shown to be essential for regulating membrane repair and has been shown to be protective against cardiac I-R and various forms of skeletal muscle injury. The purpose of this study was to determine if recombinant human MG53 (rhMG53) administration offered protection against I-R.

Methods: rhMG53 was administered to rats immediately before tourniquet-induced ischemia and again immediately before reperfusion. Two days later muscle damage was assessed histologically.

Results: rhMG53 offered no protective effect, as evidenced primarily by similar Evans blue dye inclusion in the muscles of rats administered rhMG53 or saline.

Conclusions: Administration of rhMG53 does not offer protection against I-R in rat skeletal muscle. Additional studies are required to determine if the lack of a response is species-specific.

Keywords: MG53; TRIM72; ischemia-reperfusion; muscle injury; tourniquet.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Carrier Proteins / administration & dosage
  • Carrier Proteins / pharmacology
  • Carrier Proteins / therapeutic use*
  • Disease Models, Animal
  • Humans
  • Injections, Intravenous
  • Male
  • Muscle, Skeletal / blood supply
  • Muscle, Skeletal / injuries*
  • Muscle, Skeletal / pathology
  • Necrosis / prevention & control
  • Rats, Sprague-Dawley
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use*
  • Reperfusion Injury / etiology
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Tourniquets / adverse effects*
  • Treatment Outcome
  • Tripartite Motif Proteins


  • Carrier Proteins
  • Recombinant Proteins
  • TRIM72 protein, human
  • Tripartite Motif Proteins